Clinical Trial Update: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab as maintenance therapy after thoracic chemoradiotherapy in frail patients with thorax-limited small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: UNICANCER | Conditions: Small Cell Lung Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING